BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 24223100)

  • 1. Proteomic profiling identifies distinct protein patterns in acute myelogenous leukemia CD34+CD38- stem-like cells.
    Kornblau SM; Qutub A; Yao H; York H; Qiu YH; Graber D; Ravandi F; Cortes J; Andreeff M; Zhang N; Coombes KR
    PLoS One; 2013; 8(10):e78453. PubMed ID: 24223100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between CD34/CD38 and side population (SP) defined leukemia stem cell compartments in acute myeloid leukemia.
    Moshaver B; Wouters RF; Kelder A; Ossenkoppele GJ; Westra GAH; Kwidama Z; Rutten AR; Kaspers GJL; Zweegman S; Cloos J; Schuurhuis GJ
    Leuk Res; 2019 Jun; 81():27-34. PubMed ID: 31002948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Normal hematopoietic stem cells within the AML bone marrow have a distinct and higher ALDH activity level than co-existing leukemic stem cells.
    Schuurhuis GJ; Meel MH; Wouters F; Min LA; Terwijn M; de Jonge NA; Kelder A; Snel AN; Zweegman S; Ossenkoppele GJ; Smit L
    PLoS One; 2013; 8(11):e78897. PubMed ID: 24244383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunoprofiling of leukemic stem cells CD34+/CD38-/CD123+ delineate FLT3/ITD-positive clones.
    Al-Mawali A; Gillis D; Lewis I
    J Hematol Oncol; 2016 Jul; 9(1):61. PubMed ID: 27465508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leukemic Stem Cell (CD34
    Mohamed MMI; Aref S; Agdar MA; Mabed M; El-Sokkary AMA
    Clin Lymphoma Myeloma Leuk; 2021 Aug; 21(8):508-513. PubMed ID: 33931379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High GPR56 surface expression correlates with a leukemic stem cell gene signature in CD34-positive AML.
    Daga S; Rosenberger A; Quehenberger F; Krisper N; Prietl B; Reinisch A; Zebisch A; Sill H; Wölfler A
    Cancer Med; 2019 Apr; 8(4):1771-1778. PubMed ID: 30848055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD34
    Zeijlemaker W; Grob T; Meijer R; Hanekamp D; Kelder A; Carbaat-Ham JC; Oussoren-Brockhoff YJM; Snel AN; Veldhuizen D; Scholten WJ; Maertens J; Breems DA; Pabst T; Manz MG; van der Velden VHJ; Slomp J; Preijers F; Cloos J; van de Loosdrecht AA; Löwenberg B; Valk PJM; Jongen-Lavrencic M; Ossenkoppele GJ; Schuurhuis GJ
    Leukemia; 2019 May; 33(5):1102-1112. PubMed ID: 30542144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phenotyping and Target Expression Profiling of CD34
    Blatt K; Menzl I; Eisenwort G; Cerny-Reiterer S; Herrmann H; Herndlhofer S; Stefanzl G; Sadovnik I; Berger D; Keller A; Hauswirth A; Hoermann G; Willmann M; Rülicke T; Sill H; Sperr WR; Mannhalter C; Melo JV; Jäger U; Sexl V; Valent P
    Neoplasia; 2018 Jun; 20(6):632-642. PubMed ID: 29772458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia AML.
    Herrmann H; Blatt K; Shi J; Gleixner KV; Cerny-Reiterer S; Müllauer L; Vakoc CR; Sperr WR; Horny HP; Bradner JE; Zuber J; Valent P
    Oncotarget; 2012 Dec; 3(12):1588-99. PubMed ID: 23249862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD45
    Heo SK; Noh EK; Ju LJ; Sung JY; Jeong YK; Cheon J; Koh SJ; Min YJ; Choi Y; Jo JC
    BMC Cancer; 2020 Apr; 20(1):285. PubMed ID: 32252668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells.
    van Rhenen A; van Dongen GA; Kelder A; Rombouts EJ; Feller N; Moshaver B; Stigter-van Walsum M; Zweegman S; Ossenkoppele GJ; Jan Schuurhuis G
    Blood; 2007 Oct; 110(7):2659-66. PubMed ID: 17609428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD34+CD38-CD123+ Cells Are Present in Virtually All Acute Myeloid Leukaemia Blasts: A Promising Single Unique Phenotype for Minimal Residual Disease Detection.
    Al-Mawali A; Pinto AD; Al-Zadjali S
    Acta Haematol; 2017; 138(3):175-181. PubMed ID: 29065396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disulfiram/copper selectively eradicates AML leukemia stem cells in vitro and in vivo by simultaneous induction of ROS-JNK and inhibition of NF-κB and Nrf2.
    Xu B; Wang S; Li R; Chen K; He L; Deng M; Kannappan V; Zha J; Dong H; Wang W
    Cell Death Dis; 2017 May; 8(5):e2797. PubMed ID: 28518151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determination of P-glycoprotein, MDR-related protein 1, breast cancer resistance protein, and lung-resistance protein expression in leukemic stem cells of acute myeloid leukemia.
    de Figueiredo-Pontes LL; Pintão MC; Oliveira LC; Dalmazzo LF; Jácomo RH; Garcia AB; Falcão RP; Rego EM
    Cytometry B Clin Cytom; 2008 May; 74(3):163-8. PubMed ID: 18200595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long term maintenance of myeloid leukemic stem cells cultured with unrelated human mesenchymal stromal cells.
    Ito S; Barrett AJ; Dutra A; Pak E; Miner S; Keyvanfar K; Hensel NF; Rezvani K; Muranski P; Liu P; Larochelle A; Melenhorst JJ
    Stem Cell Res; 2015 Jan; 14(1):95-104. PubMed ID: 25535865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Senescence effects of Angelica sinensis polysaccharides on human acute myelogenous leukemia stem and progenitor cells.
    Liu J; Xu CY; Cai SZ; Zhou Y; Li J; Jiang R; Wang YP
    Asian Pac J Cancer Prev; 2014 Jan; 14(11):6549-56. PubMed ID: 24377566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD34(+)/CD38(-) stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab/ozogamicin.
    Herrmann H; Cerny-Reiterer S; Gleixner KV; Blatt K; Herndlhofer S; Rabitsch W; Jäger E; Mitterbauer-Hohendanner G; Streubel B; Selzer E; Schwarzinger I; Sperr WR; Valent P
    Haematologica; 2012 Feb; 97(2):219-26. PubMed ID: 21993666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delineation of target expression profiles in CD34+/CD38- and CD34+/CD38+ stem and progenitor cells in AML and CML.
    Herrmann H; Sadovnik I; Eisenwort G; Rülicke T; Blatt K; Herndlhofer S; Willmann M; Stefanzl G; Baumgartner S; Greiner G; Schulenburg A; Mueller N; Rabitsch W; Bilban M; Hoermann G; Streubel B; Vallera DA; Sperr WR; Valent P
    Blood Adv; 2020 Oct; 4(20):5118-5132. PubMed ID: 33085758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [In Vitro Identification and Characteristics of CD34
    Zhang YH; Yang L; Wang YZ; Kong Y; Zhu HH; Qin YZ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Oct; 25(5):1289-1294. PubMed ID: 29070097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A clinically relevant population of leukemic CD34(+)CD38(-) cells in acute myeloid leukemia.
    Gerber JM; Smith BD; Ngwang B; Zhang H; Vala MS; Morsberger L; Galkin S; Collector MI; Perkins B; Levis MJ; Griffin CA; Sharkis SJ; Borowitz MJ; Karp JE; Jones RJ
    Blood; 2012 Apr; 119(15):3571-7. PubMed ID: 22262762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.